Health Care

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector

HCA Healthcare Shows Strong Pulse In Q1, Keeps 2025 Outlook Healthy

What's Going On With Summit Therapeutics Stock On Friday?

HCA Healthcare Shows Strong Pulse In Q1, Keeps 2025 Outlook Healthy

What's Going On With Summit Therapeutics Stock On Friday?

Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy

Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift

Health Care Recent News

Insurer Centene Reaffirms Annual Profit Guidance, Reports Better Than Expected Q1 Earnings

Centene raised its 2025 premium revenue outlook by $6 billion, citing strong Marketplace and Medicare Advantage performance in Q1.

Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan

Thermo Fisher plans $2 billion U.S. investment amid tariff concerns, while analysts lower price targets despite reaffirming positive ratings.

West Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Drag

West Pharmaceutical topped Q1 estimates and raised 2025 guidance, citing stronger device demand and improved inventory trends across key markets.

Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform

Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China.

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Penumbra Q1 earnings beat estimates with strong sales and thrombectomy growth; analysts raise targets as company reaffirms 2025 guidance.

ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast

ResMed posted Q3 EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens

Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong global demand.

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.

Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact

Bristol Myers reported Q1 revenue of $11.2 billion, raised 2025 guidance, and saw strong Growth Portfolio sales offset Legacy product declines.

Merck's Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million

Merck posted Q1 adjusted EPS of $2.22 and revenue of $15.53 billion, beating estimates while revising full-year guidance amid tariff-related cost pressure.

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.